Measurement of serum levels of IL-6 in patients with pancreatic cancer revealed that it is more highly expressed in these patients than in healthy controls.[18] Recent data from the literature revealed the critical role of IL-6 and its signaling pathways in pancreatic cancer oncogenesis through JAK2-STAT3 activation.[19] Furthermore, IL-6 participates in pancreatic cancer oncogenesis, metastasis, treatment resistance via mesothelin-protein kinase B-NF-kB (MSLN-Akt-NF-kB), and overexpression of IL-6-Induced myeloid leukemia cell differentiation protein (IL-6-Mcl-1).[20]. The gene discussed is MSLN; the disease is familial pancreatic carcinoma.